A Clinical Phase I / II Trial of Belinostat in Combination With Erlotinib in Patients With Non-small Cell Lung Cancer.
Phase of Trial: Phase I/II
Latest Information Update: 09 Jul 2015
At a glance
- Drugs Belinostat (Primary) ; Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 30 Dec 2010 First patient dosed, according to a Spectrum Pharmaceuticals media release.
- 29 Dec 2010 Planned number of patients changed from 58 to 35, according to a TopoTarget media release.
- 29 Dec 2010 First patient enrolled, according to a TopoTarget media release.